PET-CT in Staging, Response Evaluation, and Surveillance of Lymphoma

Research output: Contribution to journalReview article

5 Scopus citations

Abstract

Lymphoma represents a broad spectrum of diseases with diverse biology, clinical behavior, and imaging features. Functional imaging with 18-F-fluorodeoxyglucose (FDG)-positron emission tomography combined with computed tomography (PET-CT) is widely recognized as the most sensitive and specific imaging modality for patients with lymphoma and is used as part of staging, response evaluation, and surveillance in patients with Hodgkin (HL) and non-Hodgkin lymphoma (NHL). Recent efforts at standardizing the conduct and consensus interpretation of PET-CT have facilitated its use in patients on clinical studies and beyond. The role of PET-CT has been affirmed in some clinical situations, such as staging and end-of-treatment evaluation in Hodgkin lymphoma and diffuse large B cell lymphoma (DLBCL), and in the evaluation of aggressive transformation of an indolent lymphoma. However, the role of functional imaging in other histologies and clinical settings is not as clear given the higher rate of false positive results and the costs inherent to PET-CT. There is little evidence to suggest its utility or impact on outcome in most indolent lymphomas, or in the setting of post-treatment surveillance. In addition, there remains controversy about the value of PET-CT in early response assessment during active therapy, particularly in DLBCL. This review will evaluate the evidence surrounding the role of PET-CT in staging, response evaluation and surveillance of Hodgkin and non-Hodgkin lymphoma.

Original languageEnglish (US)
Article number24
JournalCurrent Treatment Options in Oncology
Volume17
Issue number5
DOIs
StatePublished - May 1 2016

    Fingerprint

Keywords

  • Functional imaging
  • Hodgkin lymphoma
  • Non-Hodgkin lymphoma
  • PET-CT scan

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this